Unmet needs in the scientific approach to older patients with lymphoma

B cell lymphoma; Burkitt lymphoma; Editorial; Follicular Lymphoma International Prognostic Index; Geriatric Depression Scale; International Prognostic Scoring System; Lawton instrumental activities of daily living scale; Mini Mental State Examination; Montreal cognitive assessment

Disciplines :

Hematology

Author, co-author :

Bron, D.; Department of Hematology, Institut Jules Bordet (ULB), Brussels, Belgium

Aurer, I.; Hematological Malignancies Unit, University Hospital Centre Zagreb, Croatia

Bonnet, Christophe ; Université de Liège - ULiège > GIGA-R : Hématologie

Caballero, D.; Department of Hematology, Complejo Asistencial Universitario de Salamanca, Spain

Falandry, C.; Unité de Gériatrie, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, UniversitéLyon 1, France

Kimby, E.; Department of Hematology, Karolinska Institute Huddinge University Hospital Stockholm, Sweden

Soubeyran, P.; Institut Bergonié, Bordeaux, France

Zucca, E.; Lymphoma Unit -Division of Research -IOSI, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Bosly, A.; CHU Dinant Godinne (CHUUCL Namur), Belgium

Coiffier, B.; Department of Hematology, Hospices Civils de Lyon, France

André, Marc; Department of Hematology, CHU Dinant Godinne (CHU UCL Namur), Belgium

Language :

English

Title :

Unmet needs in the scientific approach to older patients with lymphoma

Publication date :

2017

Journal title :

Haematologica

ISSN :

0390-6078

eISSN :

1592-8721

Publisher :

Ferrata Storti Foundation

Volume :

102

Issue :

Pages :

972-975

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 July 2018

Statistics

Number of views

106 (13 by ULiège)

Number of downloads

79 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

[No authors listed] A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040-2045.
Hamaker ME, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. Leuk Res. 2014;38(3):275-283.
Kenis C, Heeren P, Bron D, et al. Multicenter implementation of geriatric assessment in Belgian patients with cancer: a survey on treating physicians’ general experiences and expectations. J Geriatr Oncol. 2014;5(4):431-438.
Dubruille S, Libert Y, Maerevoet M, et al. Prognostic value of neuropsychological and biological factors in clinically fit older patients with hematological malignancies admitted to receive chemotherapy. Geriatr Oncol. 2015;6(5):362-369.
Petit-Monéger A, Rainfray M, Soubeyran P, Bellera CA, Mathoulin-Pélissier S. Detection of frailty in elderly cancer patients: Improvement of the G8 screening test. J Geriatr Oncol. 2016;7(2):99-107.
Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93(6):1031-1040.
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al. MabThera International Trial (MInT) Group. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. Lancet Oncol. 2008;9(5):435-444.
Peyrade F, Gastaud L, Ré D, Pacquelet-Cheli S, Thyss A. Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol. 2012;13(8):e344-352.
Ricciuti G, Finolezzi E, Luciani S, et al. Combination of rituximab and nonpegylated liposomal doxorubicin (R-NPLD) as front-line therapy for aggressive non-Hodgkin lymphoma (NHL) in patients 80 years of age or older: a single-center retrospective study. Hematol Oncol. 2017 Feb 3. [Epub ahead of print]
Marchesi F, Cenfra N, Altomare L, et al. A retrospective study on 73 elderly patients (≥75years) with aggressive B-cell non Hodgkin lymphoma: clinical significance of treatment intensity and comprehensive geriatric assessment. J Geriatr Oncol. 2013;4(3):242-248.
Molina-Garrido MJ, Guillen-Ponce C. Where Are We Headed With Research in Frail Elderly Patients With Cancer? J Clin Oncol. 2016;34(33):4049-4050.
Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377-3386.
Luciani A, Biganzoli L, Colloca G, et al. Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13). J Geriatr Oncol. 2015;6(4): 272-279.
Choi MR, Solid CA, Chia VM, et al. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy. Support Care Cancer. 2014;22(6):1619-1628.
Pfreundschuh M. How I treat elderly patients with diffuse large Bcell lymphoma. Blood. 2010;116(24):5103-5110.
Carson KR, Riedell P, Lynch R, et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. J Geriatr Oncol. 2015;6(3):211-218.
Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93(6):1031-1040.